ASH 2022 | Smoldering myeloma: the challenges of ‘watch and wait’ versus early intervention
Romanos Sklavenitis-Pistofidis
• 16 Dec 2022
Romanos Sklavenitis-Pistofidis, MD, Dana-Farber Cancer Institute, Boston, MA, comments on the challenges of choosing between early intervention versus the standard ‘watch and wait’ approach when treating patients with smoldering multiple myeloma (SMM), and further highlights the need for more data in this space. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
